Cargando…
The Efficacy and Safety of YAG Laser Vitreolysis for Symptomatic Vitreous Floaters of Complete PVD or Non-PVD
INTRODUCTION: To evaluate and compare the efficacy and safety of YAG laser vitreolysis in treating symptomatic vitreous floaters of complete posterior vitreous detachment (PVD) and non-PVD. METHODS: In this prospective cohort study, 51 eyes with symptomatic floaters were treated with YAG laser vitre...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8770727/ https://www.ncbi.nlm.nih.gov/pubmed/34778916 http://dx.doi.org/10.1007/s40123-021-00422-6 |
_version_ | 1784635429494980608 |
---|---|
author | Lin, Tiezhu Li, Tongtong Zhang, Xinmei Hui, Yannian Moutari, Salissou Pazo, Emmanuel Eric Dai, Guangzheng Shen, Lijun |
author_facet | Lin, Tiezhu Li, Tongtong Zhang, Xinmei Hui, Yannian Moutari, Salissou Pazo, Emmanuel Eric Dai, Guangzheng Shen, Lijun |
author_sort | Lin, Tiezhu |
collection | PubMed |
description | INTRODUCTION: To evaluate and compare the efficacy and safety of YAG laser vitreolysis in treating symptomatic vitreous floaters of complete posterior vitreous detachment (PVD) and non-PVD. METHODS: In this prospective cohort study, 51 eyes with symptomatic floaters were treated with YAG laser vitreolysis. Participants were divided into complete PVD and non-PVD groups. Objective visual quality measures including the Strehl ratio (SR), internal spherical aberration (SA), internal comatic aberration (CA), internal high-order aberration (HOA), area ratio of modulation transfer function (MTFa) and Vitreous Floaters Symptom Questionnaire (VFSQ-13) scores were used to compare the efficacy of YAG laser vitreolysis treatment between two groups. RESULTS: The mean age of all patients was 56.80 ± 10.82 years old. In total, 36 of 51 (70.59%; 95% CI 58.10–83.10) patients reported their symptoms as significant or complete improvement after YAG laser vitreolysis treatment. Post-treatment MTFa, internal SA and internal HOA were significantly better compared to baseline (26.19 ± 14.73 vs. 29.19 ± 17.98, p = 0.013; 0.05 ± 0.05 vs. 0.04 ± 0.04, p = 0.031 and 0.23 ± 0.22 vs. 0.16 ± 0.07, p = 0.044; respectively) in all eyes. Twenty-nine of 51 (56.86%) eyes had floaters of non-PVD type. Significant or complete subjective improvements in the PVD group and non-PVD group were 72.73% and 68.97% (p = 0.344), respectively. CONCLUSIONS: Improved subjective and objective visual quality in participants with symptomatic floaters following YAG laser vitreolysis was found in both groups. The efficacy of YAG laser vitreolysis was comparable in floaters of complete PVD and non-PVD types. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40123-021-00422-6. |
format | Online Article Text |
id | pubmed-8770727 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-87707272022-02-02 The Efficacy and Safety of YAG Laser Vitreolysis for Symptomatic Vitreous Floaters of Complete PVD or Non-PVD Lin, Tiezhu Li, Tongtong Zhang, Xinmei Hui, Yannian Moutari, Salissou Pazo, Emmanuel Eric Dai, Guangzheng Shen, Lijun Ophthalmol Ther Original Research INTRODUCTION: To evaluate and compare the efficacy and safety of YAG laser vitreolysis in treating symptomatic vitreous floaters of complete posterior vitreous detachment (PVD) and non-PVD. METHODS: In this prospective cohort study, 51 eyes with symptomatic floaters were treated with YAG laser vitreolysis. Participants were divided into complete PVD and non-PVD groups. Objective visual quality measures including the Strehl ratio (SR), internal spherical aberration (SA), internal comatic aberration (CA), internal high-order aberration (HOA), area ratio of modulation transfer function (MTFa) and Vitreous Floaters Symptom Questionnaire (VFSQ-13) scores were used to compare the efficacy of YAG laser vitreolysis treatment between two groups. RESULTS: The mean age of all patients was 56.80 ± 10.82 years old. In total, 36 of 51 (70.59%; 95% CI 58.10–83.10) patients reported their symptoms as significant or complete improvement after YAG laser vitreolysis treatment. Post-treatment MTFa, internal SA and internal HOA were significantly better compared to baseline (26.19 ± 14.73 vs. 29.19 ± 17.98, p = 0.013; 0.05 ± 0.05 vs. 0.04 ± 0.04, p = 0.031 and 0.23 ± 0.22 vs. 0.16 ± 0.07, p = 0.044; respectively) in all eyes. Twenty-nine of 51 (56.86%) eyes had floaters of non-PVD type. Significant or complete subjective improvements in the PVD group and non-PVD group were 72.73% and 68.97% (p = 0.344), respectively. CONCLUSIONS: Improved subjective and objective visual quality in participants with symptomatic floaters following YAG laser vitreolysis was found in both groups. The efficacy of YAG laser vitreolysis was comparable in floaters of complete PVD and non-PVD types. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40123-021-00422-6. Springer Healthcare 2021-11-15 2022-02 /pmc/articles/PMC8770727/ /pubmed/34778916 http://dx.doi.org/10.1007/s40123-021-00422-6 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Original Research Lin, Tiezhu Li, Tongtong Zhang, Xinmei Hui, Yannian Moutari, Salissou Pazo, Emmanuel Eric Dai, Guangzheng Shen, Lijun The Efficacy and Safety of YAG Laser Vitreolysis for Symptomatic Vitreous Floaters of Complete PVD or Non-PVD |
title | The Efficacy and Safety of YAG Laser Vitreolysis for Symptomatic Vitreous Floaters of Complete PVD or Non-PVD |
title_full | The Efficacy and Safety of YAG Laser Vitreolysis for Symptomatic Vitreous Floaters of Complete PVD or Non-PVD |
title_fullStr | The Efficacy and Safety of YAG Laser Vitreolysis for Symptomatic Vitreous Floaters of Complete PVD or Non-PVD |
title_full_unstemmed | The Efficacy and Safety of YAG Laser Vitreolysis for Symptomatic Vitreous Floaters of Complete PVD or Non-PVD |
title_short | The Efficacy and Safety of YAG Laser Vitreolysis for Symptomatic Vitreous Floaters of Complete PVD or Non-PVD |
title_sort | efficacy and safety of yag laser vitreolysis for symptomatic vitreous floaters of complete pvd or non-pvd |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8770727/ https://www.ncbi.nlm.nih.gov/pubmed/34778916 http://dx.doi.org/10.1007/s40123-021-00422-6 |
work_keys_str_mv | AT lintiezhu theefficacyandsafetyofyaglaservitreolysisforsymptomaticvitreousfloatersofcompletepvdornonpvd AT litongtong theefficacyandsafetyofyaglaservitreolysisforsymptomaticvitreousfloatersofcompletepvdornonpvd AT zhangxinmei theefficacyandsafetyofyaglaservitreolysisforsymptomaticvitreousfloatersofcompletepvdornonpvd AT huiyannian theefficacyandsafetyofyaglaservitreolysisforsymptomaticvitreousfloatersofcompletepvdornonpvd AT moutarisalissou theefficacyandsafetyofyaglaservitreolysisforsymptomaticvitreousfloatersofcompletepvdornonpvd AT pazoemmanueleric theefficacyandsafetyofyaglaservitreolysisforsymptomaticvitreousfloatersofcompletepvdornonpvd AT daiguangzheng theefficacyandsafetyofyaglaservitreolysisforsymptomaticvitreousfloatersofcompletepvdornonpvd AT shenlijun theefficacyandsafetyofyaglaservitreolysisforsymptomaticvitreousfloatersofcompletepvdornonpvd AT lintiezhu efficacyandsafetyofyaglaservitreolysisforsymptomaticvitreousfloatersofcompletepvdornonpvd AT litongtong efficacyandsafetyofyaglaservitreolysisforsymptomaticvitreousfloatersofcompletepvdornonpvd AT zhangxinmei efficacyandsafetyofyaglaservitreolysisforsymptomaticvitreousfloatersofcompletepvdornonpvd AT huiyannian efficacyandsafetyofyaglaservitreolysisforsymptomaticvitreousfloatersofcompletepvdornonpvd AT moutarisalissou efficacyandsafetyofyaglaservitreolysisforsymptomaticvitreousfloatersofcompletepvdornonpvd AT pazoemmanueleric efficacyandsafetyofyaglaservitreolysisforsymptomaticvitreousfloatersofcompletepvdornonpvd AT daiguangzheng efficacyandsafetyofyaglaservitreolysisforsymptomaticvitreousfloatersofcompletepvdornonpvd AT shenlijun efficacyandsafetyofyaglaservitreolysisforsymptomaticvitreousfloatersofcompletepvdornonpvd |